The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients

Mirte M. Malingré(Meander Medisch Centrum), Jos H. Beijnen(Utrecht University), Heleen A. Bardelmeijer(Slotervaartziekenhuis), Olaf van Tellingen(Dutch Cancer Society), Hilde Rosing(The Netherlands Cancer Institute), Mariët Ouwehand, J. Schellens(Utrecht University), Margaret Schot(The Netherlands Cancer Institute), W.W. ten Bokkel Huinink, F J Koopman(Slotervaartziekenhuis)
British Journal of Cancer
November 1, 2001
10.1054/bjoc.2001.2118
Cited by 72

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688